Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
DG80IS
|
|||
| Drug Name |
MEDI2228
|
|||
| Drug Type |
Antibody drug conjugate
|
|||
| Indication | Multiple myeloma [ICD-11: 2A83; ICD-10: C90] | Phase 1 | [1] | |
| Company |
AstraZeneca
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | B-cell maturation protein (TNFRSF17) | Target Info | Inhibitor | [2] |
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT03489525) MEDI2228 in Subjects With Relapsed/Refractory Multiple Myeloma (MEDI2228). U.S. National Institutes of Health. | |||
| REF 2 | A novel BCMA PBD-ADC with ATM/ATR/WEE1 inhibitors or bortezomib induce synergistic lethality in multiple myeloma. Leukemia. 2020 Aug;34(8):2150-2162. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.